June30 2004
Advertisement
Advertisement
Trending on HCPLive
1
Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial
2
GLP-1 Discontinuation Cuts Chances of Meeting Weight Loss, Glycemic Goals in T2D
3
VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes
4
ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial
5